Integral Molecular is a research-driven biotechnology company creating innovative technologies and therapeutic antibodies for under-exploited membrane protein targets, including GPCRs, ion channels, transporters, and viral envelopes.

July 27, 2010

Integral Molecular Announces Key Patent Issued on Lipoparticle Technology for Deriving High Concentrations of Cell-free Membrane Proteins

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, Inc. today announced the issuance of a key patent covering its technology for deriving high concentrations of membrane proteins. The patent, issued by […]
November 3, 2009

Integral Molecular Awarded $9.1 Million Contract from NIAID to Map Epitopes on Viral Pathogens using Shotgun Mutagenesis Mapping Technology

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, Inc. has been selected to receive a five year, $9.1 million contract from the National Institute of Allergy and Infectious Disease (NIAID), part […]